Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology

Hypertrophic cardiomyopathy (HCM) is a heterogeneous group of heart muscle disorders that affects millions, with an incidence from 1 in 500 to 1 in 200. Factors such as genetics, age, gender, comorbidities, and environmental factors may contribute to the course of this disease. Diagnosis of HCM has...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ewelina Młynarska, Ewa Radzioch, Bartłomiej Dąbek, Klaudia Leszto, Alicja Witkowska, Witold Czarnik, Weronika Jędraszak, Jacek Rysz, Beata Franczyk
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-11-01
coleção:	Biomedicines
Assuntos:	cardiomyopathies hypertrophic cardiomyopathy mavacamten cardiac therapeutics
Acesso em linha:	https://www.mdpi.com/2227-9059/12/12/2675
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!